alexa D-serine Effects In A Schizophrenia Patient Positive For Anti NMDAR Antibodies | 63476
ISSN: 1745-7580

Immunome Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

8th Molecular Immunology and Immunogenetics Congress

Uriel Heresco-Levy
Hebrew University, Israel
Posters & Accepted Abstracts: J Immunome Res
DOI: 10.4172/1745-7580.C1.012
Abstract
Since anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was first described a decade ago, the family of disorders associated with antibodies (AB) against neuronal surface antigens is one of the most rapidly expanding categories of neurologic disease. We hypothesized that: 1) anti-NMDAR-ABs seropositive patients can be identified among chronic treatment-resistant schizophrenia patients having atypical disease characteristics; and 2) treatment with D-serine (DSR), which acts in vivo as NMDAR co-agonist at the NR1 receptor subunit will be beneficial for the patients. Out of 17 DSM-IV-diagnosed schizophrenia patients, a 67 yr old female patient hospitalized since age 27 was seropositive for both IgG and IgM anti-NR1 AB isotypes. There was no evidence of other diseases, including malignancy. Brain MRI revealed non-specific cortical FLAIR/T2 signal hyperintensities and cEEG showed extreme delta brush (EDB) events. The patient entered a 6 wk clinical trial with DSR in doses increased gradually from 1.5 to 4 g/day. This treatment was well tolerated and resulted in increased DSR serum levels from 0.93 to 103.1 μM. No side effects were registered. Positive and Negative Syndrome Scale (PANSS) symptom clusters improved and PANSS total score decreased by 34%. The quality of life of the patient, as assessed by schizophrenia quality of life scale (SQLS) improved considerably (37% total score reduction). At 6 wks, cEEG showed significant reduction of EDB-type activity. This pilot investigation: 1) supports the hypothesis that a subgroup of treatment-resistant patients diagnosed with schizophrenia may suffer from an NMDAR-related autoimmune disorder; and 2) indicates that DSR may represent a novel type of treatment for these patients.
Biography

Uriel Heresco-Levy is a Full Professor of Psychiatry at Hadassah Medical School, Hebrew University and Director of the Psychiatry Department at Herzog Memorial Hospital, Jerusalem, Israel. He is a Member of the European College of Neuropsychopharmacology (ECNP) and Fellow of Collegium International Neuro- Psychopharmacologicum (CINP). He has conducted pioneer clinical trials with N-methyl-D-aspartate receptor (NMDAR) modulators, including glycine, D-serine and D-cycloserine and has published extensively on the role of NMDAR-mediated neurotransmission and D-serine in neuropsychiatric disorders. He is the inventor of patents focusing on the use of NMDAR-neurotransmission pharmacomodulation in Parkinson's disease, major depressive disorder and autoimmune NMDAR encephalopathies.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7